The high prices for specialty drugs are forcing physicians, patients and their families to factor in financial toxicity when choosing an appropriate therapy.
The Senate Finance Committee's first formal hearing on drug prices with HHS Secretary Alex Azar failed to firm up policy goals even as heightened congressional scrutiny puts drugmakers on edge.
A panel that advises Congress and HHS on Medicaid policy recommended tweaking the Medicaid drug rebate program to reduce spending on drugs by hundreds of millions of dollars.
Although more generic drugs are coming through the pipeline, generic competition won't affect 46% of the estimated sales revenue of the top 100 drugs through 2023, according to a new report.
The Senate is clearing the way this week for a bipartisan bill supported by insurers and provider groups aimed at easing generic drugs' entry into the market, although the legislation's future in the House and Senate is unclear.
Eighty percent of nearly 750 providers, payers and pharmaceutical companies polled said they are optimistic that the new health system-led generic-drug company will change the status quo, and 90% said they would buy drugs from it, according to a new survey.
Commentary: Trump's proposals on drug prices are right to focus on anti-competitive market practices
There are proposals in President Donald Trump's plan that if implemented could ensure stronger competition from generic and biosimilar medicines and thereby increase access and provide financial relief for patients at the pharmacy counter.
In most transactions, consumers can decide whether price and value are aligned. There's competition, a free flow of information regarding the product, and transparency regarding pricing. Not so with prescription drugs.
Generic-drug manufacturers, which source most of their active ingredients from China and India, could be hit the hardest by President Donald Trump's proposed tariffs, experts said.
A shortage of injectable opioids that's expected to last to mid-2019 is forcing providers to delay or cancel surgeries.
Modern Healthcare's CEO Power Panel survey indicates healthcare leaders still fear unbridled drug costs and wonder if the industry has reached a breaking point.
The new health system-led generic-drug company sent a shockwave through the healthcare industry, but experts warned that it would take plenty of time and capital to ultimately lower drug prices and mitigate shortages.